GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B8704 SevofluraneSummary: A non-competitive inhibitor of the 5-HT3 receptor -
B8668 Bambuterol (hydrochloride)Summary: An oral long-acting β 2-adrenergic receptor agonist -
C8682 Urotensin II (114-124, human) TFASummary: A neuropeptide agonist of the urotensin II receptor -
C8684 MCH(human, mouse, rat) TFASummary: A potent peptide agonist of MCH-R -
C8686 (-)-Isoproterenol hydrochlorideSummary: A β-adrenergic receptor agonist -
C8717 Cholecystokinin octapeptide ammoniumSummary: A sulfated CCK peptide -
C8718 Degarelix acetateSummary: A GnRH antagonist -
C8723 (-)-Norepinephrine (+)-bitartrateSummary: An effective adrenergic receptor (AR) agonist, commonly used to induce animal models of cardiomyopathy. -
N2888 Lysine Vasopressin acetateSummary: Agonists of G protein-coupled receptors V1a, V1b, and V2 -
C8724 (-)-Norepinephrine hydrochlorideSummary: An effective adrenergic receptor (AR) agonist, commonly used to induce cardiomyopathy animal models.

